AARDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Aardvark Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$3.74−0.04 (-1.06%)

Close on Oct 19, 2026

Market cap: $81.70M
P/E (TTM): –
Dividend yield: –

Aardvark Therapeutics, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31
Depreciation & Amortization	0.04	0.02
Stock-Based Compensation	3.95	0.44
Change in Accounts Payable	0.24	0.80
Operating Cash Flow	-54	-18
Capital Expenditures	-0.10	-0.11
Purchase of Investments	-130	-12
Investing Cash Flow	-50	-12
Stock Issued	0.20	0
Financing Cash Flow	89	82
Free Cash Flow	-54	-18

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -221.5%

Financial strength

Current ratio: 12.63
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1156.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.09
Dividend yield: –